Genomics & Genetics Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Breast Cancer

sHER-2/neu status predictive indicator for benefit from paclitaxel chemotherapy

According to recent research from Germany, "Elevated levels of the extracellular domain of HER-2/neu in serum (sHER-2/neu) have been shown to be of prognostic importance. In this phase II study with weekly paclitaxel in metastatic breast cancer, we investigated the predictive quality of this serum oncoprotein by correlating the outcome of therapy to sHER-2/neu levels."

"Paclitaxel (90 mg/m² weekly x6, q9w) was administered to 35 patients with complete outcome assessment and biochemical follow-up. sHER-2/neu was measured using standardized enzyme-linked...

• View Other Issues of Genomics & Genetics Weekly
  
• View Other NewsRx Publications